All In Biotech

NDA 203312 · Impax

Rytary

Carbidopa, Levodopa · Oral · Aromatic Amino Acid Decarboxylation Inhibitor; Aromatic Amino Acid

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 7, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

262

53 Phase 3, 16 recruiting

FAERS reports

21,049

8,549 serious, 2,347 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 29, 2026.

Carbidopa and levodopa extended-release capsules are indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa and levodopa extended-release capsule is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication ( 1 )

Mechanism: Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • RYTARY · CARBIDOPA 48.75MG; LEVODOPA 195MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • RYTARY · CARBIDOPA 23.75MG; LEVODOPA 95MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • RYTARY · CARBIDOPA 61.25MG; LEVODOPA 245MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • RYTARY · CARBIDOPA 36.25MG; LEVODOPA 145MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.

All 262 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,301
  • tremor2,054
  • hallucination1,815
  • fall1,747
  • dyskinesia1,614
  • dizziness1,387
  • nausea1,255
  • death1,087
  • parkinson^s disease1,000
  • somnolence968
  • fatigue932
  • gait disturbance897

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200496
200592
200685
2007107
2008224
2009122
2010150
2011141
2012134
201331
201467
2015322
2016589
20172,115
20181,669
20192,686
20202,616
20212,415
20222,107
20231,515
20241,464
20251,437
2026865

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rytary (Carbidopa/Levodopa)

2024 spending

$272M

Beneficiaries

34,890

224,759 claims

Per beneficiary

$7,790

$4.26 per unit

View as table
YearSpending
2020$164,501,794
2021$192,390,418
2022$228,311,453
2023$266,869,488
2024$271,784,313

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 545 on PubMed

Sponsor: Impax

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.